- Status:
- Topic prioritisation
- Technology type:
- Medicine
- Decision:
- Not selected
- Prioritisation programme:
- Medicines evaluation
- Rationale:
The NICE-Wide Prioritisation Board met on 16 April 2026 and concluded that an evaluation would not be appropriate for this product. The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except where there is a clear rationale not to do so. Decision makers concluded that the clear rationale to not evaluate this product is due to the proposed extension being a new dosing regimen that is not expected to impact the cost and clinical effectiveness of the published guidance within TA915. Please see eligibility criteria within the prioritisation manual for further information.
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 April 2026 | Prioritisation board meeting |
For further information on how we select topics for development, please see our page about topic prioritisation